Back to search

Article

Nanobody Armed T Cells Endow CAR-T Cells the Ability to Against Lymphoma Cells

2021-06-04

Abstract excerpt

<title>Abstract</title> <p>BackgroundTaking advantages of nanobody (Nb) in immunotherapy, here we investigate the cytotoxicity of Nb based Chimeric antigen receptor T cells (Nb CAR-T) against Lymphoma cells.MethodsCD19 Nb CAR-T, CD20 Nb CAR-T, and Bispecific Nb CAR-T cells were generated by panning anti-human CD19, CD20 specific nanobodies sequences from naive phage display library, then integrating Nb genes with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d4d32940-6322-5df6-a9a5-60dbe8809186
DOI
10.21203/rs.3.rs-546282/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Nanobody Armed T Cells Endow CAR-T Cells the Ability to Against Lymphoma CellsDOI 10.21203/rs.3.rs-546282/v1
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cellsSemantic proximity
The Application of Nanobody in CAR-T TherapySemantic proximity
Nanobody-based CAR-T cells for cancer immunotherapySemantic proximity
CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity
The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsSemantic proximity
Engineering human Mucosal Associated Invariant T (MAIT) cells with chimeric antigen receptors for cancer immunotherapy <sup>1</sup>Semantic proximity
An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemiaSemantic proximity
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesSemantic proximity
Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity
Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer ImmunotherapySemantic proximity
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignanciesSemantic proximity
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T <sub>SCM</sub> cells using <i>qCART</i> , the <i>Quantum pBac</i> -based CAR-T systemSemantic proximity
Select a neighboring publication to make it the new centre.